( New study demonstrates 75% of patients ...)Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog,Liraglutide, Brings Patients to A1c Target,Health

CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- According to findings presented today at the 67th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois, the investigational treatment liraglutide, a once- daily dose of human GLP-1 analog under development by Novo Nordisk for the treatment of type 2 diabetes significantly improved glycemic control (A1c) by reducing both fasting and post-meal glucose levels in people with type 2 diabetes. The Phase 2 study included 226 Japanese patients with type 2 diabetes treated over a period of 14 weeks. Results showed that liraglutide was effective and well tolerated within a wide dose range, allowing nearly 75 percent of patients receiving the highest dose to achieve glycemic control (A1c<7.0%) without hypoglycemia.(1)

"One challenge with insulin and many oral antidiabetic agents, which boost insulin secretion or heighten insulin sensitivity, is that they can lower blood glucose levels, resulting in hypoglycemia, which can sometimes be dangerous," said Professor Yutaka Seino, Director of Kansai-Denryoku Hospital and professor, Department of Metabolism & Clinical Nutrition, Graduate School of Medicine, Kyoto University, and lead investigator on the trial. "A well- tolerated agent with once-daily administration that can allow a majority of patients to achieve good glycemic control with a low risk of hypoglycemia and no weight gain is very promising and will be a considerable advance in diabetes treatment."

Liraglutide acts to lower blood glucose when levels are elevated, and previous studies have shown it is associated with a low risk of hypoglycemia.(2)(3)

About the Study (Abstract #0520-P)

In the study, 226 Japanese type 2 diabetes patients treated with diet or a single oral anti-diabetic drug, discontinued
'"/>